Loading…
REVB
Revelation Biosciences Inc
NASDAQ· Healthcare· Biotechnology· CUSIP 76135L804
$1.05+1.94%Price as of Aug 29, 18:47 UTC · updated once a day, after the close
Key metrics
- Market cap
- $4.18M
- P/E
- 0.0x
- Forward P/E
- —
- P/B
- 0.4x
- Dividend yield
- —
- Payout
- —
- EPS
- $27.16
- ROE
- -154.77%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- -0.17
- 52-week high
- $11.60
- 52-week low
- $0.88
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -100.0% over 5Y.
today you would have $0.00▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 6 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $3.20 | $88.51 | $2,885.76 | $38,304.00 | $2,056,320.00 | $2,026,080.00 | |
| P/B | 3.7x | 1.3x | 1.4x | 3.7x | 28.5x | — | 26.7x |
| EPS | -$23.95 | -$1,052.16 | -$101.28 | -$28,646.40 | -$244,800.00 | -$137,088.00 | |
| ROE | -100.59% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| JAGXJaguar Health, Inc. | $0.81 | 0.0x | — | — | -548.83% | $4.19M |
| GRIGRI Bio, Inc. | $1.92 | — | 0.4x | — | -142.02% | $4.2M |
| XRTXXORTX Therapeutics Inc. | $2.34 | — | 1.6x | — | -99.24% | $4.25M |
| APVOAptevo Therapeutics Inc. | $2.37 |
About the company
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
- 8
- San Diego, United States
Company description provided by Yahoo Finance.